CSRxP STATEMENT ON THE PASSING OF DAVID MITCHELL
Jan 5, 2026
Founder and President of Patients for Affordable Drugs Was a Tireless and… Read More
© 2026 CSRXP- All Rights Reserved
Updates
CSRxP: BIG PHARMA RINGS IN 2026 WITH MORE THAN 300 PRICE INCREASES ON BRAND NAME DRUGS, OUTPACING START OF 2025
Jan 5, 2026
Big Pharma Giants Including Pfizer and GSK Kickoff a New Year with Price Hikes… Read More
Dose Of Reality: Breaking Down Big Pharma’s Year of Bad Behavior in 2025: Part IV: Big Pharma’s Debunked Innovation Rhetoric
Dec 31, 2025
Big Pharma Undercut Its Own False Claims About Innovation in 2025 With each… Read More
Dose Of Reality: Breaking Down Big Pharma’s Year of Bad Behavior in 2025: Part III: Big Pharma’s Anti-Competitive Tactics That Keep Prices High
Dec 30, 2025
Exploring Big Pharma’s Egregious Abuse of the Patent System Designed to… Read More
Dose Of Reality: Breaking Down Big Pharma’s Year of Bad Behavior in 2025: Part II: Big Pharma’s DTC Advertising
Dec 29, 2025
Big Pharma’s Aggressive Marketing Directly Targeting Consumers to Boost… Read More
Dose of Reality: Breaking Down Big Pharma’s Year of Bad Behavior in 2025: Part I: Big Pharma’s Egregious Pricing Practices
Dec 29, 2025
Take a Look Back on Big Pharma’s Year of Price Hikes and Increasingly… Read More
THEY SAID IT! U.S. REPRESENTATIVE DAVE TAYLOR CALLS FOR LIST PRICE TRANSPARENCY IN BIG PHARMA’S DIRECT-TO-CONSUMER ADVERTISING
Dec 17, 2025
Lawmaker Highlights Broad-Based Support for Bipartisan Solution to Disclose… Read More
THEY SAID IT! BIPARTISAN GROUP OF LAWMAKERS URGE ADMINISTRATION TO SUPPORT CRACKDOWN ON BIG PHARMA’S PATENT THICKETS
Dec 16, 2025
Members of Congress Say Addressing “Patent Thickets Surrounding Branded… Read More
ICYMI: SKINNY LABELS, BIG SAVINGS ACT INTRODUCED IN U.S. HOUSE
Dec 9, 2025
Bipartisan Solution Would Help Bring More Generics and Biosimilars to Market,… Read More
CSRxP APPLAUDS U.S. HOUSE PASSAGE OF Q1/Q2 REFORMS TO FOSTER GREATER COMPETITION IN THE PRESCRIPTION DRUG MARKETPLACE
Dec 2, 2025
Bipartisan, Market-Based Solution Would Increase Transparency… Read More
DOSE OF REALITY: STUDY FURTHER HIGHLIGHTS THE COST OF BIG PHARMA’S BLOCKBUSTER BAILOUT
Nov 20, 2025
Analysis Finds Excluding Brand Name Drugs Approved to Treat Rare Diseases from… Read More
DOSE OF REALITY: JAMA NETWORK ANALYSIS SHINES LIGHT ON HOW BIG PHARMA PUSHES SALES OF HIGH-PRICED BLOCKBUSTERS BY TARGETING CONSUMERS ON SOCIAL MEDIA
Nov 19, 2025
Brand Name Drug Companies Sidestep Guardrails Meant to Protect American… Read More